AL
IMI

Aspiriant LLC’s Intermolecular, Inc. IMI Stock Holding History

Aspiriant LLC’s Portfolio IMI Stock Details IMI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-67,246
Closed -$61K – 221
2017
Q2 		$61K Hold
67,246
– – 0.01% 209
2017
Q1 		$63K Buy
+67,246
New +$70.2K 0.01% 212

Other funds holding IMI

RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
SPM
Symmetry Peak Management Radnor, Pennsylvania $369M AUM 148.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

Aspiriant LLC's IMI Position: Q3 2017 in Review

Aspiriant LLC sold out of Intermolecular, Inc. (IMI) in Q3 2017, closing a stake of 67,246 shares — an estimated $61K sold.

Aspiriant LLC first reported a position in IMI in Q1 2017 and held it in 2 quarters. The position peaked at $63K in Q1 2017. 20 funds tracked by Wall St. Rank hold IMI as of Q3 2017.

  • Aspiriant LLC reported no remaining Intermolecular, Inc. position as of Q3 2017 after selling out during the quarter.
  • Aspiriant LLC sold 67,246 Intermolecular, Inc. shares in Q3 2017, an estimated $61K.
  • Aspiriant LLC first reported a position in Intermolecular, Inc. in Q1 2017 and held it in 2 quarters.
  • Aspiriant LLC's Intermolecular, Inc. position peaked at $63K in Q1 2017.
  • 20 funds tracked by Wall St. Rank held Intermolecular, Inc. as of Q3 2017.

Based on Aspiriant LLC's 13F filing for Q3 2017, filed 13 Nov 2017.